GCG and obesity disorder: The new glucagon-like peptide-1 obesity drugs reduce caloric intake—only during treatment72—and appear to act in synergy with lifestyle interventions.73,74 It is compelling to consider the success and cost-effectiveness that could result from combining a drug that works while on treatment with a lifestyle intervention that works after treatment is discontinued.